QuartrQuartr

PEG: Net loss improved to DKK -2.7m, with strengthened IP and ongoing licensing discussions

Thời gian đọc: dưới 1 phút

Net loss narrowed to DKK -2.7m in H1 2026, driven by cost reductions and a DKK 5.6m Portinho receivable revaluation. Clinical and IP progress continued, with new patents and ongoing licensing discussions. Guidance reflects uncertainty around licensing and clinical study timing.

Original document: Pharma Equity Group A/S Class A [PEG] Slides Release — Aug. 14 2026

Thông báo miễn trừ trách nhiệm